New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Do you recommend a workup for POEMS and/or amyloidosis for IgM monoclonal gammopathies associated with neuropathy?

1
4 Answers

Mednet MemberInvited Expert
Medical Oncology · Brigham and Women's Hospital

While IgM monoclonal disorders, amyloidosis, and POEMS syndrome may all be associated with peripheral neuropathy, they are not often confused with one another. A patient with a peripheral neuropathy can be diagnosed most simply by a serum protein electrophoresis. The presence of a monoclonal IgM spi...

How do you approach CNS prophylaxis in patients with DLBCL?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · Abramson Cancer Center, Perelman School of Medicine University of Pennsylvania

Given the overall risk of CNS relapse for DLCL in our current era of chemoimmunotherapy is around 5%, the key to an algorithm for CNS prophylaxis is based on risk to avoid the risks of overtreatment. There are several methods of prognostication that have been published, which can identify groups wit...

Would you supplement iron for low iron studies in absence of anemia?

1
2 Answers

Mednet MemberInvited Expert
Hematology · Georgetown University School of Medicine

The answer is absolutely and positively. Iron deficiency causes symptoms independent of anemia which include fatigue, brain fog, restless legs syndrome, and pagophagia and other forms of pica. You simply cannot dignify waiting for overt iron deficiency to develop in someone with symptomatic iron def...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What is your treatment approach for MAG antibody-associated polyneuropathy?

2
2 Answers

Mednet MemberInvited Expert
Neurology · Brown University

When patients have a classic Distal acquired demyelinating sensory (DADS) Neuropathy phenotype (by clinical +/- EDX criteria), typically an SPEP/IFE is checked first, and if an IgM monoclonal gammopathy is observed, then I typically check MAG antibodies at that point (if clinical and EDX features ar...

How do you work up patients with low level monoclonal lymphocytosis and adenopathy?

1
5 Answers

Mednet MemberInvited Expert
Medical Oncology · UPMC Hillman Cancer Center

Asymptomatic patients who have MBL (<5 x 10⁹/L malignant B-cells in blood) and associated lymph node disease that is palpable have the diagnosis of CLL/SLL. If they are asymptomatic, I do not scan these individuals or biopsy the palpable lymph node. My approach here would be to: Initiate prognostic...

What is your approach to iron supplementation in patients with an active infection?

5
3 Answers

Mednet MemberInvited Expert
Hospital Medicine · Yale School of Medicine/Yale New Haven Hospital

In patients with active infections, I generally avoid intravenous iron due to the potential for promoting pathogen growth, a practice supported by cautions from nephrology and gastroenterology society guidelines. However, evidence for the risk of infection with IV iron is inconsistent, underpowered,...

What platelet threshold, if any, is your goal for cytoreduction in essential thrombocythemia?

1
1 Answers

Mednet MemberInvited Expert
Hematology · Johns Hopkins University

An unusual feature of the myeloproliferative neoplasms (MPN) is that their driver mutations are gain-of-function, meaning that the basic MPN phenotype is the increased proliferation of normal circulating blood cells. This basic phenotype is modified by host genetic variation to create three genetica...

How do you approach management of symptomatic myelofibrosis in transplant-ineligible patients with severe thrombocytopenia, e.g., platelets in the 20s, who have an inadequate response to pacritinib?

2 Answers

Mednet MemberInvited Expert
Hematology · University of Chicago

This is a very difficult clinical scenario and, unfortunately, a common one in advanced myelofibrosis!Regarding the thrombocytopenia, we typically use a transfusion threshold of 10K in the absence of bleeding. The data for TPO agonist use in myelofibrosis are quite sparse, so I typically don't utili...

After the MAJESTEC-3 results, what is your approach to choosing between tec-dara vs. cilta-cel versus another triplet for multiple myeloma in first relapse?

3
7 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center

This is an excellent question, and literally a million-dollar question for various companies involved. It's worth noting that the US FDA can change the package insert at will (and has done so) compared to what the trials did, so there's no guarantee as of yet that Tec-Dara (based on MajesTEC-3) will...

How do you approach laboratory assessment for anticoagulation adherence when working up anticoagulation failure?

1 Answers

Mednet MemberInvited Expert
Hematology · University of Rochester School of Medicine and Dentistry

When faced with an anticoagulation failure, my go-to test for adherence is looking at the medication-dispense report (if you have this available at your institution, it is very handy for understanding the patient's adherence to anticoagulation). Typically, this will either show intermittent dispensi...